Expression of metallothionein and Nrf2 pathway genes in lung cancer and cancer-surrounding tissues

[1]  A. Hengstermann,et al.  Nrf2: friend and foe in preventing cigarette smoking-dependent lung disease. , 2012, Chemical research in toxicology.

[2]  Tsonwin Hai,et al.  Loss of metallothionein predisposes mice to diethylnitrosamine-induced hepatocarcinogenesis by activating NF-kappaB target genes. , 2010, Cancer research.

[3]  M. Fraga,et al.  Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis , 2010, Melanoma research.

[4]  J. Pi,et al.  Nrf2 in toxicology and pharmacology: the good, the bad and the ugly? , 2010, Toxicology and applied pharmacology.

[5]  Curtis D. Klaassen,et al.  Nrf2 the rescue: effects of the antioxidative/electrophilic response on the liver. , 2010, Toxicology and applied pharmacology.

[6]  A. Naba,et al.  Inhibition of endothelial cell chemotaxis toward FGF-2 by gefitinib associates with downregulation of Fes activity. , 2009, International journal of oncology.

[7]  M. Kanda,et al.  Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. , 2009, International journal of oncology.

[8]  M. McMahon,et al.  Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. , 2009, Carcinogenesis.

[9]  Manuela Gariboldi,et al.  Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma , 2008, Laboratory Investigation.

[10]  P. Laird,et al.  DNA methylation profile of 28 potential marker loci in malignant mesothelioma. , 2007, Lung cancer.

[11]  Shu-Hui Zhang,et al.  Downregulated expression of metallothionein and its clinicopathological significance in hepatocellular carcinoma , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[12]  K. Robertson,et al.  Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer , 2007, Oncogene.

[13]  Rui Henrique,et al.  MT1G Hypermethylation Is Associated with Higher Tumor Stage in Prostate Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[14]  M. Zabel,et al.  Role of metallothionein expression in non-small cell lung carcinomas. , 2004, Roczniki Akademii Medycznej w Bialymstoku.

[15]  A. Jayasurya,et al.  Metallothioneins in human tumors and potential roles in carcinogenesis. , 2003, Mutation research.

[16]  K. Ghoshal,et al.  Suppression of metallothionein-I/II expression and its probable molecular mechanisms. , 2002, Environmental health perspectives.

[17]  S. Theocharis,et al.  Expression of metallothionein in lung carcinoma: correlation with histological type and grade , 2002, Histopathology.

[18]  Jie Liu,et al.  Metallothionein: an intracellular protein to protect against cadmium toxicity. , 1999, Annual review of pharmacology and toxicology.

[19]  J. Ward,et al.  Down-regulation of metallothionein expression in human and murine hepatocellular tumors: association with the tumor-necrotizing and antineoplastic effects of cadmium in mice. , 1996, The Journal of pharmacology and experimental therapeutics.

[20]  J. Ward,et al.  Further evidence of the tumor-suppressive effects of cadmium in the B6C3F1 mouse liver and lung: late stage vulnerability of tumors to cadmium and the role of metallothionein. , 1993, The Journal of pharmacology and experimental therapeutics.